Your session is about to expire
← Back to Search
Behavioural Intervention
FRx-001 for Attention Deficit Hyperactivity Disorder (ADHD)
N/A
Waitlist Available
Research Sponsored by Revibe Technologies
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to post-intervention (4 weeks)
Awards & highlights
Summary
This trial looks at how digital devices can help kids with ADHD manage symptoms and improve their functioning.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline to post-intervention (4 weeks)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to post-intervention (4 weeks)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
ADHD Rating Scale-5 (ADHD-RS-5), School Version: Inattention Subscale
Secondary outcome measures
ADHD Rating Scale-5, Home Version: Inattention Subscale
ADHD Rating Scale-5, Home Version: Total score
ADHD Rating Scale-5, School Version: Total score
Other outcome measures
ADHD Rating Scale-5, Home Version: Hyperactivity-Impulsivity Subscale
ADHD Rating Scale-5, School Version: Hyperactivity-Impulsivity Subscale
Academic Performance Rating Scale
+7 moreTrial Design
3Treatment groups
Active Control
Group I: FRx-001Active Control1 Intervention
FRx-001 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and scheduled assistive messaging.
Group II: FRx-003Active Control1 Intervention
FRx-003 is a wearable digital intervention that provides therapeutic vibrations to the subjects wrist and may include periodic assistive messaging.
Group III: FRx-004Active Control1 Intervention
FRx-004 is a wearable digital intervention that displays periodic therapeutic assistive messaging.
Find a Location
Who is running the clinical trial?
Revibe TechnologiesLead Sponsor
Share this study with friends
Copy Link
Messenger